ZNF384 and acute lymphoblastic leukemia: In addition, SJ6986 has shown significant effects in the single drug treatment of high-risk ALL patient-derived xenograft (PDX) models, including the treatment of hypodiploid ALL, Ph-like ALL, and ZNF384 rearranged mixed-phenotype acute leukemia.